Mettler-Toledo International (MTD) vs 10x Genomics (TXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
10x Genomics (TXG) has outperformed Mettler-Toledo International (MTD) over the past year, gaining 556.0% versus a gain of 17.1%. Over five years, MTD leads with a +8.2% price change compared with -50.0% for TXG. Mettler-Toledo International is the larger company by market cap ($30.73 billion vs $9.92 billion), about 3.1 times the size, while 10x Genomics is growing revenue faster (+5.2% vs +4.0%).
On valuation, Mettler-Toledo International trades at a lower forward P/E (29.6x vs 992.6x for 10x Genomics). Mettler-Toledo International converts more of its revenue into profit, with a net margin of 21.6% versus -6.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MTD | TXG |
|---|---|---|
| Share price | $1,533.48 | $76.10 |
| Market cap | $30.73B | $9.92B |
| 1-day change | +0.03% | -5.65% |
| YTD return | +9.99% | +366.58% |
| 1-year return | +17.14% | +556.03% |
| 5-year return | +8.16% | -50.02% |
| P/E ratio (TTM) | 34.55 | — |
| Forward P/E | 29.62 | 992.57 |
| EPS (TTM) | $44.38 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.03B | $642.82M |
| Revenue growth (YoY) | +3.98% | +5.25% |
| Net income (latest FY) | $869.19M | $-43.54M |
| Gross margin | 59.37% | 69.05% |
| Operating margin | — | -9.49% |
| Net margin | 21.59% | -6.77% |
| 52-week high | $1,585.72 | $102.81 |
| 52-week low | $1,023.05 | $11.16 |
| Distance from 52-week high | -3.29% | -25.98% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -4.04% | -13.27% |
| Average volume | 183.40K | 3.15M |
| Shares outstanding | 20.04M | 120.21M |
| Employees | 16,600 | 1,178 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Mettler-Toledo International is about 3.1 times larger than 10x Genomics by market value ($30.73B vs $9.92B).
- TXG has outperformed MTD by 538.9 percentage points over the past year.
- Mettler-Toledo International is more profitable, keeping 21.6 cents of every revenue dollar as net income versus -6.8 cents for 10x Genomics.
About Mettler-Toledo International
MTD stock →Mettler-Toledo International Inc. manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally.
Industrials · Biotechnology: Laboratory Analytical Instruments · 16,600 employees
About 10x Genomics
TXG stock →10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
Industrials · Biotechnology: Laboratory Analytical Instruments · 1,178 employees
MTD vs TXG FAQ
Which is bigger, Mettler-Toledo International or 10x Genomics?
Mettler-Toledo International (MTD) is larger, with a market capitalization of $30.73B compared with $9.92B for 10x Genomics (TXG).
Which stock has performed better over the past year, MTD or TXG?
TXG returned +556.03% over the past 12 months, compared with +17.14% for MTD (price return, excluding dividends). Past performance does not predict future results.
Are Mettler-Toledo International and 10x Genomics in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.